We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed at $58.75 in the latest trading session, marking a -5.01% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. On the other hand, the Dow registered a loss of 0.7%, and the technology-centric Nasdaq increased by 0.18%.
Shares of the drugstore chain and pharmacy benefits manager have depreciated by 6.81% over the course of the past month, underperforming the Medical sector's gain of 2.39%, and the S&P 500's gain of 5.71%.
Market participants will be closely following the financial results of CVS Health in its upcoming release. The company plans to announce its earnings on July 31, 2025. It is anticipated that the company will report an EPS of $1.47, marking a 19.67% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $93.72 billion, indicating a 2.73% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.12 per share and revenue of $385.5 billion. These totals would mark changes of +12.92% and +3.4%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CVS Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.32% higher. CVS Health is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, CVS Health currently has a Forward P/E ratio of 10.11. This signifies a discount in comparison to the average Forward P/E of 15.73 for its industry.
Meanwhile, CVS's PEG ratio is currently 0.88. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. CVS's industry had an average PEG ratio of 1.52 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
CVS Health (CVS - Free Report) closed at $58.75 in the latest trading session, marking a -5.01% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. On the other hand, the Dow registered a loss of 0.7%, and the technology-centric Nasdaq increased by 0.18%.
Shares of the drugstore chain and pharmacy benefits manager have depreciated by 6.81% over the course of the past month, underperforming the Medical sector's gain of 2.39%, and the S&P 500's gain of 5.71%.
Market participants will be closely following the financial results of CVS Health in its upcoming release. The company plans to announce its earnings on July 31, 2025. It is anticipated that the company will report an EPS of $1.47, marking a 19.67% fall compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $93.72 billion, indicating a 2.73% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.12 per share and revenue of $385.5 billion. These totals would mark changes of +12.92% and +3.4%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CVS Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.32% higher. CVS Health is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, CVS Health currently has a Forward P/E ratio of 10.11. This signifies a discount in comparison to the average Forward P/E of 15.73 for its industry.
Meanwhile, CVS's PEG ratio is currently 0.88. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. CVS's industry had an average PEG ratio of 1.52 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.